XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $848K invested in XTL Biopharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
21% more capital invested
Capital invested by funds: $699K → $848K (+$149K)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$9.71K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.8K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $378K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $378K | – | – | – |
|
|
3
Morgan Stanley
New York
| $90K | +$9.71K | +1,400 | +13% |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | +$1.8K | +259 | New |
|
XTLB Hedge Fund Activity: Q3 2020 in Review
4 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2020, worth a combined $848K — up 21% from $699K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $9.71K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2020, up from 3 in Q2 2020.
- Funds reported $848K of XTL Biopharmaceuticals stock for Q3 2020, up 21% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2020 was Morgan Stanley, an estimated $9.71K added.
Based on aggregated 13F filings for Q3 2020.